Supernus Pharmaceuticals Files 8-K
Ticker: SUPN · Form: 8-K · Filed: Feb 18, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Feb 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, sec-filing
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K, looks like standard financial disclosures, nothing major.
AI Summary
On February 18, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No new financial figures or significant business updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Supernus Pharmaceuticals is providing routine updates and disclosures to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no indication of significant new risks or events.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- February 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 20850 (zip_code) — Zip code of principal executive offices
- Rockville (city) — City of principal executive offices
- MD (state) — State of principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals?
The primary purpose of this 8-K filing is to report Other Events and Financial Statements and Exhibits, as indicated by the filing's item information.
On what date was this 8-K report filed or effective?
The report was filed as of February 18, 2025, and the date of the earliest event reported is also February 18, 2025.
What is Supernus Pharmaceuticals, Inc.'s state of incorporation?
Supernus Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Supernus Pharmaceuticals, Inc.?
The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.
Does this filing indicate any specific new product launches or regulatory approvals?
The provided excerpt of the 8-K filing does not detail any specific new product launches or regulatory approvals; it focuses on 'Other Events' and 'Financial Statements and Exhibits'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).